Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ANEB 
Anebulo Pharmaceuticals Inc (ANEB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: ANEB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -58.18% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 112.98M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 2 | Beta -0.89 | 52 Weeks Range 0.80 - 3.42 | Updated Date 10/27/2025 |
52 Weeks Range 0.80 - 3.42 | Updated Date 10/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -71.09% | Return on Equity (TTM) -109.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 86975505 | Price to Sales(TTM) - |
Enterprise Value 86975505 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.54 | Shares Outstanding 41084731 | Shares Floating 3401405 |
Shares Outstanding 41084731 | Shares Floating 3401405 | ||
Percent Insiders 40.54 | Percent Institutions 54.14 |
Upturn AI SWOT
Anebulo Pharmaceuticals Inc
Company Overview
History and Background
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing novel solutions to address substance abuse, starting with overdoses of prescription opioids and potentially other substances of abuse.
Core Business Areas
- Opioid Overdose Reversal: Focuses on developing ANEB-001, a competitive antagonist designed to reverse the effects of opioid overdose. They are conducting clinical trials to evaluate its safety and efficacy.
Leadership and Structure
The company is led by a management team with experience in drug development and commercialization. Details on the specific organizational structure are publicly available.
Top Products and Market Share
Key Offerings
- ANEB-001: ANEB-001 is a competitive antagonist for reversing opioid overdose. It is currently in clinical trials. Specific market share data isn't yet available since the drug is not yet approved. Competitors include companies developing naloxone-based products and other opioid antagonists such as Opiant Pharmaceuticals, Inc.
Market Dynamics
Industry Overview
The industry focuses on developing drugs and treatments for substance abuse, particularly opioid overdose. Increased awareness of the opioid crisis has driven demand for effective treatments.
Positioning
Anebulo is positioned as a company developing a new approach to opioid overdose reversal using a competitive antagonist. Their potential advantage lies in addressing limitations of existing treatments.
Total Addressable Market (TAM)
The TAM for opioid overdose reversal is estimated to be substantial, driven by the ongoing opioid crisis. Anebulo's positioning will depend on clinical trial outcomes and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel approach to opioid overdose reversal
- Potential to address limitations of existing treatments
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Clinical stage company with no approved products
- Reliance on successful clinical trial outcomes
- Limited financial resources
- High regulatory risk
Opportunities
- Growing market for opioid overdose reversal treatments
- Potential for partnerships with pharmaceutical companies
- Expansion into other substance abuse treatments
- Government support for addressing the opioid crisis
Threats
- Competition from established pharmaceutical companies
- Failure of clinical trials
- Regulatory hurdles
- Changes in the opioid crisis landscape
Competitors and Market Share
Key Competitors
- OPIANT Pharmaceuticals (OPNT)
- Emergent BioSolutions (EBS)
- Hikma Pharmaceuticals (HKMPF)
Competitive Landscape
Anebulo competes with established pharmaceutical companies developing naloxone-based products and other opioid antagonists. Their advantage hinges on the efficacy and safety profile of ANEB-001 compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable for a clinical-stage company.
Future Projections: Future growth depends heavily on successful clinical trial outcomes and regulatory approval for ANEB-001.
Recent Initiatives: Recent initiatives include ongoing clinical trials for ANEB-001 and efforts to secure funding.
Summary
Anebulo Pharmaceuticals is a high-risk, high-reward clinical-stage company focused on opioid overdose reversal. Its success depends on the successful development and regulatory approval of ANEB-001. The company needs to secure adequate funding and navigate a competitive landscape. Investors should closely monitor clinical trial outcomes and regulatory developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Anebulo Pharmaceuticals Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a financial professional. Market share data is based on available information and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Anebulo Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Lakeway, TX, United States | ||
IPO Launch date 2021-05-07 | CEO & Director Mr. Richard Anthony Cunningham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.anebulo.com |
Full time employees 2 | Website https://www.anebulo.com | ||
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.